Natural killer cells in patients with severe chronic fatigue syndrome.
about
Metabolic features of chronic fatigue syndromeCharacterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.Web-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting.ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients.Dysregulation of Protein Kinase Gene Expression in NK Cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients.Intermittent and graded exercise effects on NK cell degranulation markers LAMP-1/LAMP-2 and CD8+CD38+ in chronic fatigue syndrome/myalgic encephalomyelitis.Severity Scales for Use in Primary Health Care to Assess Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients
P2860
Q28829926-F9B7C7F9-EDD4-4C3B-B1F6-B9C38A4F90DDQ35648873-889E7CB9-D4A2-48D2-A7BC-F20EB1756E56Q36056594-D0CA8036-8616-4C59-A2BB-299807C74DBFQ36788528-7919FE54-3598-4833-8F35-DDC9A7C803DEQ36820322-D7BFE925-1D6A-4E62-90D8-E79AA070E7A7Q36955692-737840FC-1917-4807-9FB1-27E348B2EB2CQ37021151-48AAEC2C-C09C-4B76-97C3-87A746448CB8Q37213332-43666729-1D79-474D-AECC-A3EE4F83F6AAQ37699630-9CAC1948-951E-4567-B770-A70D3620CC3BQ38260241-BEDF1B1A-E4C6-4A60-8BC7-00D1ECD7AF36Q51733779-CA6466B2-B136-48D2-9A79-F2A485E7C803Q55387468-372B74A6-E778-4807-99BE-3DC5B7C52477Q58782400-2889DEF7-BF1B-4397-9159-691C2C9F505F
P2860
Natural killer cells in patients with severe chronic fatigue syndrome.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Natural killer cells in patients with severe chronic fatigue syndrome.
@ast
Natural killer cells in patients with severe chronic fatigue syndrome.
@en
type
label
Natural killer cells in patients with severe chronic fatigue syndrome.
@ast
Natural killer cells in patients with severe chronic fatigue syndrome.
@en
prefLabel
Natural killer cells in patients with severe chronic fatigue syndrome.
@ast
Natural killer cells in patients with severe chronic fatigue syndrome.
@en
P2093
P2860
P1476
Natural killer cells in patients with severe chronic fatigue syndrome
@en
P2093
D R Staines
G M Atkinson
M L van Driel
S L Hardcastle
S M Marshall-Gradisnik
P2860
P2888
P356
10.1007/S13317-013-0051-X
P577
2013-04-16T00:00:00Z